自身免疫性大疱病病程中的皮肤相关生活质量
这项回顾性横断面研究纳入192例自身免疫性大疱病患者(共212次就诊),发现发作期Skindex-16各领域评分均高于非发作期,且差异超过测量标准误。Skindex-16在发作期评估中显示良好构念效度,但验证性因子分析模型拟合不佳。
要点
- 发作期Skindex-16各领域评分均高于非发作期,差异超过测量标准误。
- 非发作期大疱性类天疱疮和疱疹样皮炎患者的生活质量仍差于天疱疮患者。
- Skindex-16与患者报告疾病严重度强相关,与抑郁评分中度相关。
核心结论
- 皮肤相关生活质量与自身免疫性大疱病发作高度相关。
- 非发作期大疱性类天疱疮和疱疹样皮炎患者的生活质量差于天疱疮患者,提示残余 morbidity。
- Skindex-16显示良好构念效度,但验证性因子分析模型拟合不佳,需进一步研究。
研究设计与样本
- 回顾性横断面研究,2016年9月1日至2020年2月1日在犹他大学健康自身免疫性皮肤病诊所进行。
- 纳入192例患者共212次就诊,中位年龄68岁(IQR 58-76),女性123/212(58.0%)。
- 疾病亚型包括大疱性类天疱疮、天疱疮、疱疹样皮炎和线性IgA病。
- 统计分析方法为Spearman相关和验证性因子分析。
主要发现
- 发作期Skindex-16各领域评分中位数均高于非发作期,差异超过测量标准误。
- 大疱性类天疱疮:情感领域发作期52.4(IQR 38.1-69.0)vs 非发作期7(IQR 0-17);症状领域37.5(IQR 29.2-58.0)vs 13(IQR 0-25);功能领域26.7(IQR 10.0-56.7)vs 0(IQR 0-3)。
- 天疱疮:情感领域发作期54.8(IQR 31.0-81.0)vs 非发作期0(IQR 0-19);症状领域58.3(IQR 41.7-70.8)vs 4(IQR 0-12.5);功能领域26.7(IQR 13.3-83.3)vs 0(IQR 0-3.33)。
- 疱疹样皮炎:情感领域发作期72.6(IQR 34.7-90.5)vs 非发作期14.3(IQR 2.4-26.2);症状领域69(IQR 31.3-85.4)vs 12.5(IQR 0-29.2);功能领域38.3(IQR 5.0-63.2)vs 0(IQR 0-13.3)。
- 所有领域和疾病亚型的Cronbach α均大于0.80;与抗Dsg1和抗BP180滴度呈中度或低度相关。
关键数值与推荐
- Skindex-16领域评分范围0-100,0表示对皮肤相关生活质量无影响,100表示最大影响。
- 发作期评分预期至少高于测量标准误。
- 地板或天花板效应定义为<20%样本评分为最低或最高可能领域评分。
- 收敛效度采用Spearman相关评估。
- 结构效度采用验证性因子分析评估。
临床怎么用
- 在自身免疫性大疱病中临床测量皮肤相关生活质量可提供关键疾病严重度信息。
- Skindex-16可用于评估发作期皮肤相关生活质量,但需注意其结构效度需进一步研究。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Autoimmune bullous diseases (AIBDs) are chronic relapsing-remitting conditions with significant morbidity. Skin-related quality of life (SRQL) may vary by AIBD subtype and disease type. Disease severity and flare severity can be difficult to define; SRQL can offer a key insight. OBJECTIVES: To investigate the Skindex-16 score as an SRQL measure in AIBD subtypes during flare and nonflare states and to evaluate Skindex-16 construct validity. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cross-sectional study was conducted from September 1, 2016, to February 1, 2020, among 192 patients at the University of Utah Health autoimmune dermatology clinic with pemphigoid, pemphigus, dermatitis herpetiformis, and linear immunoglobulin A disease. Patients had an encounter-associated diagnosis, Skindex-16 scores, and self-reported flare status. Statistical analysis was performed from March 2022 to June 2023. EXPOSURE: Autoimmune bullous disease subtype and patient-reported flare status. MAIN OUTCOMES AND MEASURES: Skindex-16 domain scores (emotions, symptoms, and functioning; range, 0-100, where 0 indicates no effect on SRQL and 100 maximum effect) and individual item scores were described by disease and flare status. Flare scores were expected to be higher by at least the standard error of measurement (SEm). Convergent validity was assessed using Spearman correlation among Skindex-16 scores, serologic titers, and other patient-reported outcome measures. Floor or ceiling domain scores (<20% of sample scoring either lowest or highest possible domain scores, respectively) were assessed for Skindex-16. Structural validity was assessed using confirmatory factor analysis (CFA). RESULTS: The study included 192 patients with 212 visits (median age, 68 years [IQR, 58-76 years]; 123 of 212 women [58.0%]) with Skindex-16 scores (64 in flare state and 148 in nonflare state). Median Skindex-16 domain scores were higher for all disease categories among patients in the flare state compared with those in the nonflare state (pemphigoid [emotions: flare, 52.4 (IQR, 38.1-69.0); nonflare, 7 (IQR, 0-17); symptoms: flare, 37.5 (IQR, 29.2-58.0); nonflare, 13 (IQR, 0-25); functioning: flare, 26.7 (IQR, 10.0-56.7); nonflare, 0 (IQR, 0-3)]; pemphigus [emotions: flare, 54.8 (IQR, 31.0-81.0; nonflare, 0 (IQR, 0-19); symptoms: flare, 58.3 (IQR, 41.7-70.8); nonflare, 4 (IQR, 0-12.5); functioning: flare, 26.7 (IQR, 13.3-83.3); nonflare, 0 (IQR, 0-3.33)]; dermatitis herpetiformis [emotions: flare, 72.6 (IQR, 34.7-90.5); nonflare, 14.3 (IQR, 2.4-26.2); symptoms: flare, 69 (IQR, 31.3-85.4); nonflare, 12.5 (IQR, 0-29.2); functioning: flare, 38.3 (IQR, 5.0-63.2); nonflare, 0 (IQR, 0-13.3)]. This difference exceeded SEm cut points. Cronbach α was greater than 0.80 for all domains and AIBDs. Moderate or low correlations were seen with desmoglein 1 and bullous pemphigoid 180 titers. Moderate correlation existed between Skindex-16 and Patient-Reported Outcomes Measurement Information System Depression scores (emotions: ρ = 0.40; symptoms: ρ = 0.41; functioning: ρ = 0.48), and strong correlation existed between Skindex-16 and patient-reported disease severity (emotions: ρ = 0.71; symptoms: ρ = 0.73; functioning: ρ = 0.66). Floor domain scores greater than 20% were seen among patients in the nonflare state, but ceiling domain scores were rare (<10% for all domains); CFA model fit was poor. CONCLUSIONS AND RELEVANCE: In this cross-sectional study, SRQL was highly associated with flare of AIBDs. Skin-related quality of life was worse during periods without flare among patients with pemphigoid and dermatitis herpetiformis compared with pemphigus, highlighting residual SRQL morbidity. Skindex-16 showed good construct validity, but the poor CFA model fit needs further research. Clinical measurement of SRQL in AIBDs can add critical disease-severity information.
引用
- Hopkins ZH, Jimenez A, Taliercio VL, et al. Skin-Related Quality of Life During Autoimmune Bullous Disease Course. JAMA Dermatol. 2023. PMID: 37703003. doi:10.1001/jamadermatol.2023.3121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。